

AbbVie Pipeline Update

July 2026



abbvie

AbbVie R&D Pipeline

Phase 1	Phase 2	Registrational / Phase 3	Submitted
■ ABBV-243 (β7) CD/UC ■ ABBV-313 (IL-13/IL-31R) AD ■ ABBV-319 (CD19 ADC) SLE, Sjorgren's Disease ■ ABBV-519 (CD19) RA, SLE ■ ABBV-547 (IL-23) PsO ■ ABBV-619 (CD19 CAR-T) RA, SLE ■ ABBV-722 (LPAR1i) IPF ■ ABBV-722 (LPAR1i) + Rinvoq (JAK1i) RA, SSC ■ ABBV-848 (IRAK4i) RA ■ ABBV-859 (IL-23Ri) PsO ■ ABBV-1451 (IL-1α/1β) HS ■ APG279[†] (IL-13/OX40L) AD ■ APG333[†] (TSLP) Asthma ■ Zumilokibart[†] (IL-13) Asthma ■ ABBV-324 (GPC3 ADC) HCC / SQ-NSCLC ■ ABBV-514 (CCR8) Solid Tumors ■ ABBV-711 (PARP7i) Solid Tumors ■ ABBV-901 (FRα ADC) Ovarian Cancer ■ ABBV-969 (PSMA/STEAP1 ADC) mCRPC ■ Alveltamig* (DLL3/DLL3/CD3) SCLC ■ ABBV-1480 (RC148)* (PD-1/VEGF) Solid Tumors ■ KST-6051 (KRASi)* Solid Tumors ■ Temab-A (c-Met ADC) HNSCC, Ovarian ■ ABBV-438 (CD38 ADC) R/R MM ■ ABBV-2001* (CD38/BCMA/CD3) R/R MM ■ Etentamig (BCMA/CD3) MM Combinations ■ SIM0500* (GPRC5D/BCMA/CD3) R/R MM ■ Surzetoclast (ABBV-453) (BCL2i) R/R MM ■ UB-VV111* (CD19 CAR-T) LBCL, CLL ■ ABBV-1042 (M4 Agonist) Bipolar Mania ■ ABBV-1758 (3pE-Aβ) Alzheimer's Disease ■ Emraclidine (M4 PAM) Psychosis ■ ABBV-6628 (C5) Geographic Atrophy ■ ABBV-295 (Amylin) Obesity	■ ABBV-142 (LPAR1) IPF ■ ABBV-382 (α4β7) + Skyrizi (IL-23) CD/UC ■ ABBV-701 (TL1A) + Skyrizi (IL-23) CD/UC ■ ABBV-8736 (TREM1) CD ■ Lutikizumab (IL-1α/1β) + Ravagalimab (CD40) RA ■ Lutikizumab (IL-1α/1β) + Skyrizi (IL-23) PsA ■ Zumilokibart[†] (IL-13) AD ■ ABBV-706 (SEZ6 ADC) 1L SCLC ■ Elahere (FRα ADC) Ovarian Cancer (FLORENZA) ■ IMG-151 (FRα ADC) Gynecologic Cancers ■ Temab-A (c-Met ADC) CRC ■ Temab-A (c-Met ADC) GEA ■ Temab-A (c-Met ADC) Met-Amplified Tumors ■ Temab-A (c-Met ADC) NSCLC ■ Temab-A (c-Met ADC) PDAC ■ Epkinly* (CD20/CD3) B-Cell NHL ■ Epkinly* (CD20/CD3) R/R CLL and Richter's Syndrome ■ Etentamig (BCMA/CD3) AL Amyloidosis ■ Pivekimab Sunirine (CD123 ADC) AML ■ ABBV-932* (D2/D3 Agonist) Bipolar Depression ■ ABBV-932* (D2/D3 Agonist) GAD ■ ABBV-1354 (KOR Antagonist) Bipolar Depression ■ ABBV-1354 (KOR Antagonist) MDD ■ ABBV-2002 (PAR-2) Migraine Prevention ■ Bretisilocin (5-HT2AR Agonist) MDD ■ Emraclidine (M4 PAM) Schizophrenia ■ GemibotA Essential Tremor ■ GemibotA Ventral Hernia Repair ■ ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery ■ ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) DR Suprachoroidal Delivery ■ AGN-193408 (Prostamide 408 SR) Glaucoma	■ Lutikizumab (IL-1α/1β) HS ■ Rinvoq (JAK1i) HS ■ Rinvoq (JAK1i) SLE ■ ABBV-706 (SEZ6 ADC) R/R SCLC ■ Elahere (FRα ADC) + Bevacizumab PSOC (GLORIOSA) ■ Temab-A (c-Met ADC) + Bevacizumab 3L+ CRC ■ Epkinly* (CD20/CD3) + Lenalidomide R/R DLBCL ■ Epkinly* (CD20/CD3) + R-CHOP 1L DLBCL ■ Epkinly* (CD20/CD3) + Rituximab/Lenalidomide 1L FL ■ Etentamig (BCMA/CD3) 3L+ MM ■ Qulipta (CGRP) Menstrual Migraine Prevention ■ Ubelvly (CGRP) Menstrual Migraine Prevention ■ ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Subretinal Delivery ■ Armour Thyroid (T3T4) Hypothyroidism	■ Rinvoq (JAK1i) Alopecia Areata (US) ■ Rinvoq (JAK1i) Vitiligo (US) ■ Tavapadon (D1/D5 Partial Agonist) Parkinson's Disease ■ Boey (TrenibotE) Glabellar Lines (US) ■ Reproxalap (RASPs)* Dry Eye Disease

■	Immunology
■	Oncology
■	Neuroscience
■	Aesthetics
■	Eye Care
■	Targeted Investment

New Clinical Programs: ABBV-313 Ph1 AD, ABBV-519 Ph1 RA/SLE, ABBV-859 Ph1 PsO, ABBV-1451 Ph1 HS, ABBV-382 + Skyrizi Ph2b CD/UC, ABBV-701 + Skyrizi Ph2b CD/UC, Temab-A Ph2/3 PDAC
GemibotA Ph2 Essential Tremor, ABBV-RGX-314 Ph2b DR suprachoroidal delivery

Discontinued Clinical Programs: Livmoniplimab NSCLC

As of July 31, 2026
Excludes devices in development
*AbbVie Partnered assets

AbbVie - Anticipated Key Pipeline Events

	2026	2027
Regulatory Approvals	Rinvoq Vitiligo* Skyrizi Crohn's Disease Subcutaneous Induction Epkinly + Rituximab/Lenalidomide 2L FL (INTL) ✓ Decnupaz (Pivekimab Sunirine) BPDEN ✓ Qulipta Migraine Acute Treatment (INTL) ✓ Tavapadon Parkinson's Disease	Rinvoq Alopecia Areata* Epkinly + R-CHOP 1L DLBCL Epkinly + Lenalidomide 2L DLBCL Transplant Ineligible Etentamig Monotherapy 3L MM Qulipta Menstrual Migraine Prevention (EU) Ubrely Menstrual Migraine Prevention (US) Boey (TrenibotE) Glabellar Lines*
Regulatory Submissions	Rinvoq Vitiligo ✓ Rinvoq Alopecia Areata ✓ Skyrizi Crohn's Disease Subcutaneous Induction ✓ Epkinly + R-CHOP 1L DLBCL Epkinly + Lenalidomide 2L DLBCL Transplant Ineligible Etentamig Monotherapy 3L MM Qulipta Menstrual Migraine Prevention (EU)	Lutikizumab Hidradenitis Suppurativa Rinvoq Hidradenitis Suppurativa Rinvoq Systemic Lupus Erythematosus Elahere + Bevacizumab 2L PSOC Maintenance Ubrely Menstrual Migraine Prevention (US) ABBV-RGX-314 wAMD Subretinal Delivery
Ph3/Registrational Data Readouts	Lutikizumab Ph3 Hidradenitis Suppurativa Rinvoq Ph3 Hidradenitis Suppurativa Skyrizi Ph3 Crohn's Disease Subcutaneous Induction ✓ Epkinly + R-CHOP Ph3 1L DLBCL Epkinly + Lenalidomide Ph3 2L DLBCL Transplant Ineligible ✓ Etentamig Monotherapy Ph3 3L MM Qulipta Ph3 Menstrual Migraine Prevention Ubrely Ph3 Menstrual Migraine Prevention	Rinvoq Ph3 Systemic Lupus Erythematosus Elahere + Bevacizumab Ph3 2L PSOC Maintenance Temab-A + Bevacizumab Ph3 3L+ CRC ABBV-RGX-314 Ph3 wAMD Subretinal Delivery
Early-Stage Data Readouts	ABBV-382 + Skyrizi Ph2 CD ✓ Lutikizumab + Ravaglimab Ph2 RA ABBV-969 Ph1 mCRPC ✓ ABBV-2001 Ph1 MM Etentamig Ph1 2L MM Combinations ✓ IMGN-151 Ph2 PROC Temab-A Ph2 comboTx 2L CRC ABBV-932 Ph2 Bipolar Depression ✓ Bretisiloin Ph2 MDD Emraclidine Ph2 Schizophrenia Emraclidine Ph1 Psychosis ABBV-295 Ph1 Obesity ✓ Lutikizumab + Skyrizi Ph2 CD ✓ Livmoniplimab Ph2 1L NSCLC ✓	ABBV-319 Ph1 SLE/Sjorgren's Disease ABBV-619 Ph1 RA/SLE Lutikizumab + Skyrizi Ph2 PsA ABBV-514 Ph1 Solid Tumors Etentamig Ph1 1L MM Combinations Surzetoclast Ph1 MM Temab-A Ph2 comboTx 1L CRC Temab-A Ph2 comboTx 1L GEA Temab-A Ph2 comboTx 1L NSCLC Temab-A Ph2 comboTx 1L PDAC Temab-A Ph2 monoTx 2L NSCLC EGFR-mutant ABBV-932 Ph2 Generalized Anxiety Disorder ABBV-1354 Ph2 MDD ABBV-2002 Ph2 Migraine Prevention ABBV-RGX-314 Ph2 wAMD Suprachoroidal Delivery

As of July 31, 2026

*Rinvoq approved for alopecia areata and vitiligo in Europe; Boey approved for glabellar lines in Europe

AbbVie's Partnered Assets

- ABBV-932 developed in partnership with Gedeon Richter.
- ABBV-1480 (RC148) developed in partnership with RemeGen.
- ABBV-2001 developed in partnership with Ichnos Glenmark Innovation (IGI).
- ABBV-RGX-314 co-developed by REGENXBIO and AbbVie.
- Alveltamig developed by Suzhou Zelgen Biopharmaceuticals. AbbVie holds an exclusive option to develop and commercialize Alveltamig.
- KST-6051 developed by Kestrel Therapeutics. AbbVie holds an exclusive option to acquire Kestrel.
- Epkinly developed in partnership with Genmab.
- Reproxalap currently developed by Aldeyra. AbbVie holds an exclusive option to license, co-develop, and co-commercialize reproxalap.
- SIM0500 developed by Simcere Zaiming. AbbVie holds an exclusive option to develop and commercialize SIM0500.
- UB-VV111 developed by Umoja Biopharma. AbbVie holds an exclusive option to develop and commercialize UB-VV111.